Bioburden is defined as the number in terms of percentage, colony or cell count of bacteria that thrive on a given unsterilized surface. Bioburden testing, also known as microbial limit testing provides quantification of the bacterial cell cultures on a given unsterilized surface. The major application of bioburden testing lies in implant fixation procedures that require testing ofcertain tolerable bioburden limit before implantation in the human body. The standard for bioburden testing in the US is regulated by the US FDA, whereas global standards are maintained by the ISO (International Organization for Standardization). The quantification for the standardization process is done in terms of colony forming unit (CFU).
Bioburden testing is essential in limiting the presence of infection causing bacteria in an object that is to be integrated into a human body as an implant. The testing is important to eliminate the presence of bacterial residue and growth in any object present in natural state. In addition it is almost impossible to remove bacterial residue permanently in an object that is liable to be exposed to open air. Hence sterilization process is performed on an implant object or a device post understanding the bioburden limit. This helps to select the appropriate sterilization technique in order to remove the bacterial burden just prior to the medical (Or other related) procedure. Bioburden testing has therefore saved numerous lives.
Based on technology, bioburden testing is segmented into microbial filter method, advanced colorimetric method, and plate count method. Among these, microbial filter method is the most commonly used method for bioburden testing procedures. The plate count method is among the oldest methods for bioburden testing, however is not used regularly on a large scale commercial basis due to its time consuming procedure. Advanced colorimetric method is presently the most promising and widely used bioburden testing technology. The congregation of colometer and computational capabilities has enabled advanced colometric methods to deliver quick results of quantifying bioburden.
Based on equipment, bioburden testing market can be segmented into PCR (polymerase chain reaction) instruments, cell counters, and automated microbial identification systems that are software integrated. Application segment for bioburden testing includes healthcare, aerospace (satellite production & development), supercomputer (super- microprocessor manufacturing) designing, and others (raw material, equipment cleaning, food & beverage). The healthcare industry is the largest application area of bioburden testing.
Geographically, the bioburden testing market is primarily concentrated in the North America and Asia Pacific region. The demand for bioburden testing in the Asia Pacific region is expected to grow, and very likely to replace the North America market soon. Australia, Japan, and China form the largest markets in the Asia Pacific region. South Asia and South East Asia on the other hand show great potential in terms of life sciences and raw material applications; although at present a majority of the growing bioburden testing market consists of life science applications. Besides this, a large number of contract manufacturers reside in the Asia Pacific region. On the other hand, European industries continue to remain a strong point in the global bioburden testing market mainly due to the high quality of products services offered, presence of numerous quality manufacturers and their increased reliability. However certain significant restrictions for bioburden testing remains valid in the European and North American region, such as dearth of trained technicians, overwhelming volume of service demand, and high cost of services, to name a few. The bio-burden testing market in the Rest of the World (ROW) region is expected to grow at a steady rate, albeit slower than the major economies of the world.
Some of the well known manufacturers/service providers of bioburden testing equipment/service include: Charles River Laboratories International, Inc., Sigma-Aldrich Corporation, SGS S.A., WuXi PharmaTech (Cayman), and Inc., Merck & Co., Inc., Becton, Dickinson and Company, North American Science Associates, Inc., Nelson Laboratories, Pacific Biolabs, and ATS Labs, Inc.
This research report analyzes this market on the basis of its market segments, major geographies, and current market trends.
Geographies analyzed under this research report include
Middle East and Africa
This report provides comprehensive analysis of
Market growth drivers
Factors limiting market growth
Current market trends
Market projections for upcoming years
Request a brochure of this report to know what opportunities will emerge in the rapidly evolving Bioburden Testing Market during 2015- 2023
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453